Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Vomiting 4Nausea 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 8Etoposide 6Paclitaxel 5Ifosfamide 4Sunitinib 3Oxaliplatin 3Cyclophosphamide 3Brentuximab Vedotin 3tremelimumab 2pembrolizumab 2etoposide phosphate 2durvalumab 2Sirolimus 2Gemcitabine 2Everolimus 2Epirubicin 2Dexamethasone 2Carboplatin 2Bleomycin 2Bevacizumab 2tozuleristide 1rolapitant 1ribociclib 1pegfilgrastim 1pazopanib 1olaparib 1fosaprepitant 1fludarabine phosphate 1fludarabine 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Germ Cell and Embryonal × fosaprepitant × Clear all
NCT01736917 2016-05-25

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors

Hoosier Cancer Research Network

Phase 2 Completed
65 enrolled 14 charts
Genitourinary

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡